Everest Medicines (HKSE:01952) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 25, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Everest Medicines's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Everest Medicines's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Everest Medicines's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Everest Medicines (HKSE:01952) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Everest Medicines Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p.	2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p.	2201 Interest of corporation controlled by you
Tf Capital Iv Ltd.	2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd.	2501 Other
C-bridge Healthcare Fund Gp Ii, L.p.	2501 Other
C-bridge Healthcare Fund Ii, L.p.	2501 Other
C-bridge Investment Everest Limited	2501 Other
Tf Capital Ii Ltd.	2501 Other
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Fu Wei	2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse

Everest Medicines Headlines

No Headlines